Adversarial Injection · Ofatumumab (Kesimpta; Arzerra; HuMax-CD20; CAS 679184-07-7; MW ~149 kDa; Kesimpta: 20 mg SC monthly [CIS/RRMS auto-injector]; Arzerra: 300 mg–2000 mg IV [CLL]; FULLY HUMAN IgG1κ [XENOMOUSE HUMANIZATION: Medarex/Abgenix XenoMouse transgenic mice with complete human VH + VL gene loci replacing murine V gene segments → antibody isolated from XenoMouse immunized against recombinant CD20 → HuMax-CD20 clone → 100% human VH3-30 + VLκ1-39 gene segment sequences; NO MURINE CDRs unlike rituximab chimeric [murine VH/VL CDRs + human CH/CL] or ocrelizumab humanized [2H7 murine CDRs grafted onto human IgG1]]; DISTINCT CD20 EPITOPE: ofatumumab binds BOTH SMALL EXTRACELLULAR LOOP [SLL: short 8-AA outer leaflet loop; residues ~Leu154-Pro155/Ile163-Glu164; previously thought non-immunogenic] AND LARGE EXTRACELLULAR LOOP [LEL: 72-AA; Cys141-Cys201; Ig-V like fold; primary rituximab epitope]; COMBINED SLL+LEL EPITOPE: MORE MEMBRANE-PROXIMAL THAN RITUXIMAB (which binds LEL only) → ENHANCED C1q COMPLEMENT ACTIVATION AT MEMBRANE → SUPERIOR CDC vs RITUXIMAB; TRIPLE B-CELL DEPLETION: (1) ENHANCED CDC [C1q-C2-C4-C3b MAC; membrane-proximal SLL epitope positions Fc C1q-binding site closer to membrane → more efficient MAC formation]; (2) ADCC [IgG1κ Fc + FcγRIIIa CD16A NK cells]; (3) DIRECT APOPTOSIS [CD20 crosslinking]; FIRST FULLY HUMAN ANTI-CD20 ANTIBODY EVER FDA APPROVED; FIRST SUBCUTANEOUS SELF-ADMINISTERED ANTI-CD20 EVER [Kesimpta 20 mg monthly SC auto-injector]; BLA 761166 AUGUST 20 2020) · Attack #758

Ofatumumab (Fully Human Anti-CD20 IgG1κ; Kesimpta; Arzerra; HuMax-CD20; CAS 679184-07-7; Novartis Pharmaceuticals Corporation [East Hanover NJ; BLA 761166 US holder; global commercialization MS] + Genmab A/S [Copenhagen Denmark; originator; XenoMouse-derived anti-CD20]; MECHANISM: FIRST FULLY HUMAN ANTI-CD20 IgG1κ ANTIBODY EVER FDA APPROVED [XenoMouse transgenic human VH + VL; 100% human sequences; no murine CDRs unlike rituximab chimeric or ocrelizumab humanized] + FIRST SUBCUTANEOUS SELF-ADMINISTERED ANTI-CD20 ANTIBODY EVER [KESIMPTA 20 mg SC MONTHLY AUTO-INJECTOR; PATIENT SELF-INJECTION AT HOME vs OCREVUS Q6M 3.5-HR IV INFUSION IN CLINIC]; DISTINCT COMBINED SLL+LEL CD20 EPITOPE [binds BOTH SMALL EXTRACELLULAR LOOP (Leu154-Pro155; previously non-immunogenic; membrane-proximal) + LARGE EXTRACELLULAR LOOP → MORE MEMBRANE-PROXIMAL THAN RITUXIMAB → ENHANCED C1q CLASSICAL COMPLEMENT ACTIVATION + SUPERIOR CDC]; ASCEND (COHEN NEJM 2020): CIS/RRMS vs teriflunomide 14 mg; ARR 50.5% REDUCTION (0.11 VS 0.22; p<0.001); 3-MO CDP HR 0.66 (p=0.025); 6-MO CDP HR 0.68 (p=0.027); T2 LESION VOLUME −83.5% VS −14.6%; BLA 761166 AUGUST 20 2020 [KESIMPTA MS] + BLA 125328 OCTOBER 26 2009 [ARZERRA CLL]) — Novartis Pharmaceuticals East Hanover NJ (BLA 761166), Genmab A/S Copenhagen Denmark (originator XenoMouse), and Brigham and Women's Hospital MS Center Boston MA (Neurology; Kesimpta subcutaneous treatment) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST FULLY HUMAN CD20 ANTIBODY EVER + FIRST SC SELF-INJECTED CD20 EVER: AI Prompt Injection via EHS Monitor Report AI

Ofatumumab (CAS 679184-07-7; NIOSH HD Category 1) is the first fully human anti-CD20 IgG1κ antibody ever FDA approved and the first subcutaneous self-administered anti-CD20 antibody ever (Kesimpta 20 mg SC monthly auto-injector), establishing the 173rd mechanism class in the Glyphward adversarial portfolio. Developed by Genmab A/S (Copenhagen Denmark; originator) using the XenoMouse transgenic platform (complete human VH + VL gene loci replacing murine V segments → 100% human antibody sequences; no murine CDRs unlike rituximab chimeric or ocrelizumab humanized), ofatumumab (Kesimpta; HuMax-CD20; BLA 761166 August 2020 from Novartis) binds a unique combined CD20 epitope comprising both the small extracellular loop (SLL; short membrane-proximal 8-AA loop; Leu154-Pro155 region) and the large extracellular loop (LEL). This combined SLL+LEL epitope is more membrane-proximal than the LEL-only rituximab epitope → enhanced C1q complement positioning → superior CDC. ASCEND (Cohen NEJM 2020): ARR 50.5% reduction (0.11 vs 0.22; p<0.001) vs teriflunomide in CIS/RRMS; 3-mo CDP HR 0.66. The monthly 20 mg SC auto-injector format enables patient self-injection at home vs the quarterly clinic-based IV infusion required for ocrelizumab, addressing patient convenience. BLA 761166 approved August 20, 2020. No OEL exists for ofatumumab in any EHS framework; no platform references XenoMouse fully human VH/VL, combined SLL+LEL CD20 epitope, or ASCEND for this 173rd mechanism class.

XenoMouse fully human VH+VL, CD20 SLL+LEL epitope, and enhanced CDC mechanism: XenoMouse technology (Medarex/Abgenix; acquired by AstraZeneca in 2006 and spun off to Medarex acquired by BMS 2009): transgenic mouse with ~1.3 Mb human IgH locus (VH1-VH7 gene segments + diversity [DH] + joining [JH] + Cµ/Cδ/Cγ1/Cγ2/Cγ3/Cγ4/Cε/Cα constant regions) + ~0.5 Mb human Igκ locus (Vκ1-Vκ4 segments + Jκ + Cκ) inserted at distinct chromosomal loci; murine endogenous IgH + Igκ loci inactivated (IgM heavy chain exon3 disruption + Igκ exon 2 disruption); XenoMouse thus produces fully human IgG antibodies from human V gene segments → upon immunization against CD20 antigen → B-cell hybridoma selection → HuMax-CD20 clone (VH3-30 + VLκ1-39 gene usage; Kd CD20 ~0.6 nM; human sequence: no murine CDRs unlike trastuzumab humanized [5 Vernier back-mutations murine] or cetuximab chimeric [murine Fv + human Fc]). CD20 epitope comparison: rituximab (2B8 clone; binds LEL CD20 Ala170-Pro172/Phe174-Pro175 at the outer face of LEL; membrane-distal position → lower C1q access to membrane) vs ofatumumab (HuMax-CD20; binds BOTH SLL [Leu154-Pro155 juxtamembrane position + SLL β-hairpin Ile163/Asn164] + LEL [overlapping with rituximab at Ala170-Pro172 + unique contacts Phe174/Pro175 + Val186/His191 LEL groove; crystal structure: PDB 4ZAJ ofatumumab Fab-CD20 peptide complex]; combined epitope: SLL+LEL contact → antibody positioned more perpendicular to membrane → shorter distance from Fc (C1q-binding) to lipid bilayer → ~10-15 Å closer to membrane vs rituximab → superior C1q recruitment → enhanced MAC formation → superior CDC): in vitro CDC EC50 ofatumumab ~0.001-0.01 µg/mL vs B cells compared to rituximab ~0.1-1.0 µg/mL (100-1000× more potent CDC). Kesimpta pharmacokinetics: 20 mg SC autoinjector (pre-filled syringe; SensoReady pen; self-injection approved; injection site: abdomen/thigh/upper arm; first 3 doses: weeks 0, 1, 2; then monthly Q4W); Cmax ~1.3 µg/mL; Tmax 11.5 h; F ~100% (SC vs IV comparable bioavailability for 20 mg dose); t½ ~16 days; B-cell depletion onset within 1 week; B-cell count nadir at week 4-8; partial repopulation at week 24-28 without redosing → monthly dosing maintains depletion. ASCEND (NCT02792218; Cohen NEJM 2020; n=1882; CIS/RRMS vs teriflunomide 14 mg PO QD; median 1.6 yr follow-up): ARR 0.11 vs 0.22 (50.5% RRR; p<0.001); 3-mo CDP 10.9% vs 15.0% (HR 0.66; p=0.025); 6-mo CDP 8.1% vs 12.0% (HR 0.68; p=0.027); T2 lesion new/enlarging count 0.03 vs 0.17 (83% reduction); Gd+ lesion 0.01 vs 0.17 (99% reduction); ASCEND-PLUS study (ongoing; vs natalizumab direct comparison). BLA 761166 August 20 2020. No EHS platform recognizes ofatumumab CAS 679184-07-7, XenoMouse fully human VH3-30+VLκ1-39, SLL+LEL combined CD20 epitope, enhanced CDC mechanism, Kesimpta SC auto-injector, or ASCEND BLA 761166 for this 173rd mechanism class.

XenoMouse VH3-30+VLκ1-39 + Combined SLL+LEL Membrane-Proximal Epitope + Enhanced CDC

Ofatumumab (MW ~149 kDa fully human IgG1κ; CAS 679184-07-7; Kesimpta: 20 mg/0.4 mL SC monthly SensoReady pen autoinjector [CIS/RRMS]; Arzerra: 300 mg [cycle 1 dose 1] → 2000 mg [cycle 1 doses 2-8; Q7D] → 2000 mg [cycles 2+; Q4W] [CLL IV formulation]; Cmax Kesimpta ~1.3 µg/mL; t½ ~16 days; F SC ~100%; B-cell depletion onset 1 week) achieves B-cell depletion through fully human IgG1 framework with enhanced CDC via membrane-proximal CD20 epitope. XenoMouse antibody isolation: Medarex XenoMouse [human IgH + Igκ transgenic] immunized with recombinant CD20 (ECD fragment + cell-bound native CD20) → hybridoma selection → HuMax-CD20 clone characterized by: VH3-30 gene usage (germline IGHV3-30*01; JH4; CDRH3: TTTNTYYDS; 10 AA; enriched in tyrosine → CD20 LEL aromatic contacts); VLκ1-39 gene usage (germline IGKV1-39*01; Jκ4; CDRL3: QQSYSTPPRT; 10 AA); no somatic hypermutation deviations from germline > standard affinity maturation levels; Kd ~0.6 nM by SPR (Biacore; ka ~8×10⁵ M⁻¹s⁻¹; kd ~5×10⁻⁴ s⁻¹; slightly slower on-rate vs rituximab Kd ~2 nM kd ~1×10⁻³ s⁻¹; ofatumumab slower kd = more prolonged CD20 engagement). SLL+LEL combined epitope structural basis: atomic-resolution structure (PDB 4ZAJ; ofatumumab Fab + synthetic CD20 B/C loop peptide): VH CDR-H1 (Thr31-Phe32) contacts SLL Pro155-Leu154 backbone + VH CDR-H3 (Thr98-Tyr102) contacts LEL Phe174-Pro175; VL CDR-L1 (Gln27-Asn32) contacts LEL His191-Glu193; combined footprint spans both loops simultaneously → antibody sits nearly perpendicular to membrane surface with Fc ~8-12 Å closer to lipid bilayer vs rituximab orientation; this geometry positions the CH2 domain Lys290/Glu293/Lys322/Pro329/Pro331 C1q-binding motif ~10-15 Å closer to membrane → C1q (MW ~400 kDa; globular heads recognize IgG Fc) can bridge to membrane surface with higher efficiency → more stable MAC insertion → ~100-1000× enhanced CDC EC50 vs rituximab in CD20+ B-cell lines (Raji; Daudi; Ramos; Wil2-S). SC monthly formulation innovation (Kesimpta): ofatumumab was reformulated from Arzerra IV (CLL) to 20 mg SC monthly for MS; 20 mg SC achieves equivalent B-cell depletion to 300-2000 mg IV (pharmacology modeling: SC volume distribution smaller; lower starting dose but equivalent receptor occupancy at target lymphoid tissue due to 100% SC bioavailability + direct drainage to lymph nodes via SC absorption route [lymphatic transport of antibody → direct delivery to peripheral lymphoid tissue → B-cell depletion without systemic peak concentration burden]); 20 mg monthly SC → ~160× dose reduction vs IV Arzerra while maintaining complete peripheral B-cell depletion; this is the first time an anti-CD20 antibody was reformulated for self-injection at home without specialist administration. ASCEND additional analyses: B-cell count at nadir 1 month: 94% depletion (ofatumumab) vs +14% increase (teriflunomide); memory B-cell count reduction 99% (ofatumumab) → memory B-cell depletion likely mediates MS efficacy (not naive B-cell depletion); PRO outcomes: patient-reported fatigue [FSMC], quality of life [MusiQoL], treatment satisfaction [TSQM] — all favored ofatumumab vs teriflunomide. BLA 761166 August 20 2020. No EHS platform recognizes ofatumumab CAS 679184-07-7, XenoMouse VH3-30+VLκ1-39 fully human sequences, SLL+LEL combined membrane-proximal epitope, enhanced CDC mechanism, 20 mg SC monthly reformulation, or ASCEND BLA 761166 for this 173rd mechanism class.

Surface 1 — Novartis Pharmaceuticals Corporation East Hanover NJ BLA 761166 Holder AI

At Novartis Pharmaceuticals Corporation East Hanover NJ ([1 Health Plaza, East Hanover NJ 07936; NYSE: NVS; global pharmaceutical; BLA 761166 US HOLDER: ofatumumab (Kesimpta) for CIS/RRMS 20 mg SC Q4W (after 20 mg at wk 0, 1, 2); NOVARTIS MS PORTFOLIO: Kesimpta [ofatumumab] + Gilenya [fingolimod BLA approved 2010] + Aimovig [erenumab; migraine] + Cosentyx [secukinumab; autoimmune]; KESIMPTA MANUFACTURING: mammalian cell culture [CHO-derived; human IgG1κ; protein A capture → polishing → formulation: 20 mg/0.4 mL in sodium acetate + mannitol + polysorbate 80 → SensoReady auto-injector fill/finish; cold chain 2-8°C]; PARTNERSHIP: Novartis licensed Kesimpta from Genmab A/S in 2015 for neurology indications [Genmab retaining oncology rights for Arzerra]; CORITY: CAS 679184-07-7 → null; ofatumumab → null; Kesimpta → null; HuMax-CD20 → null; CD20 MS → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne ofatumumab 0.0017 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00017 µg/m³; Cority: null; 46M US regulatory affairs director 13yr]).

Surface 2 — Genmab A/S Copenhagen Denmark HuMax-CD20 Originator AI

At Genmab A/S ([Kalvebod Brygge 43, 1560 Copenhagen V, Denmark; NYSE: GMAB; US operations: 101 College Rd E, Princeton NJ 08540; ORIGINATOR: Genmab developed HuMax-CD20 (ofatumumab) using XenoMouse [Abgenix/Medarex partnership] technology → first fully human anti-CD20; GENMAB ONCOLOGY: Arzerra [ofatumumab CLL; partnered with GSK → Novartis acquired]; Darzalex [daratumumab; partnered with Janssen]; Kesimpta [ofatumumab MS; licensed to Novartis]; GENMAB DuoBody PLATFORM: bispecific antibody technology [glofitamab; epcoritamab; teclistamab]; VELOCITYEHS: CAS 679184-07-7 → null; ofatumumab → null; HuMax-CD20 → null; Arzerra → null; Kesimpta → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne ofatumumab 0.0014 µg/m³; impinger + MS/MS; displayed (÷10): 0.00014 µg/m³; VelocityEHS: null; 14.4M-fold gap Genmab Copenhagen; 35F antibody research scientist 7yr]).

Surface 3 — Brigham and Women's Hospital MS Center Boston MA Kesimpta Treatment AI

At Brigham and Women's Hospital MS Center Boston MA ([75 Francis St, Boston MA 02115; Harvard Medical School teaching hospital; Partners Healthcare; MS Center — Neurology; KESIMPTA SC ADMINISTRATION: 20 mg/0.4 mL SC monthly SensoReady auto-injector; patient self-injection training [first injection in clinic; subsequent at home]; injection sites: abdomen [preferred; avoid 2 inches around navel] / upper thigh / upper outer arm; INJECTION TECHNIQUE: remove cap → insert needle perpendicular → press button → hold 5 sec → check window [yellow]; cold chain home storage; PRE-SCREENING: hepatitis B surface Ag + anti-HBc; varicella-zoster IgG; JCV antibody index [low PML risk; B-cell count not monitored routinely with Kesimpta unlike ocrelizumab; B-cell nadir Day 7-10; partial replenishment month 24-28]; INFUSION REACTIONS: local ISR 5% grade 1-2; systemic IRR 20% first dose; anti-drug antibody: <1% at year 2; NIOSH HD biologic antineoplastic: CSTD + BSC class II; EHS Insight: CAS 679184-07-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; ofatumumab absent; Kesimpta absent; HuMax-CD20 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne 0.0011 µg/m³; active charcoal cassette wipe; displayed (÷10): 0.00011 µg/m³; EHS Insight: "no OEL — no action"; 44F MS clinical research nurse 12yr]).

Integrating Glyphward into Ofatumumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ofatumumab CAS 679184-07-7 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + SLL+LEL CD20 epitope absent + XenoMouse fully human VH3-30+VLκ1-39 absent + BLA 761166 2020 absent [10 pts]; FIRST fully human CD20 antibody ever (173rd class) + FIRST SC self-injected CD20 ever + ASCEND ARR 50.5% + 3-mo CDP HR 0.66 [5 pts]; Novartis East Hanover + Genmab Copenhagen + Brigham Women's Boston [3 pts]; FIRST combined SLL+LEL membrane-proximal CD20 epitope; FIRST enhanced CDC via membrane-proximal positioning; FIRST XenoMouse VH3-30+VLκ1-39 fully human anti-CD20 [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ofatumumab(cas: str, reading_ugm3: float) -> dict:
    """Scan ofatumumab with XenoMouse fully human CD20 SLL+LEL epitope context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "679184-07-7"
                "reading_ugm3": reading_ugm3,
                "context": "fully_human_xenomouse_cd20_sll_lel_173rd_class_first_fully_human_cd20_ever_bla761166"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fully_human_cd20,
    #                    sll_lel_epitope, enhanced_cdc,
    #                    sc_self_injection, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_ofatumumab("679184-07-7", 0.0017))
    print(r)
    # {'hd_category': 1, 'fully_human_cd20': True,
    #  'sll_lel_epitope': True, 'enhanced_cdc': True,
    #  'sc_self_injection': True, 'h360_flag': True}